GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lannett Co Inc (OTCPK:LCINQ) » Definitions » Price-to-Owner-Earnings

Lannett Co (Lannett Co) Price-to-Owner-Earnings : (As of May. 04, 2024)


View and export this data going back to 1994. Start your Free Trial

What is Lannett Co Price-to-Owner-Earnings?

As of today (2024-05-04), Lannett Co's share price is $0.02965. Lannett Co does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Lannett Co's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Lannett Co was 943.32. The lowest was 4.83. And the median was 19.50.


LCINQ's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 28.05
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-04), Lannett Co's share price is $0.02965. Lannett Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-25.28. Therefore, Lannett Co's PE Ratio for today is At Loss.

As of today (2024-05-04), Lannett Co's share price is $0.02965. Lannett Co's EPS without NRI for the trailing twelve months (TTM) ended in was $-25.28. Therefore, Lannett Co's PE Ratio without NRI for today is At Loss.

During the past 13 years, Lannett Co's highest PE Ratio without NRI was 207.38. The lowest was 0.00. And the median was 19.08.


Lannett Co Price-to-Owner-Earnings Historical Data

The historical data trend for Lannett Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lannett Co Price-to-Owner-Earnings Chart

Lannett Co Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.00 - 55.10 - -

Lannett Co Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lannett Co's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Lannett Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lannett Co's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lannett Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Lannett Co's Price-to-Owner-Earnings falls into.



Lannett Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Lannett Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.02965/-25.62
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lannett Co  (OTCPK:LCINQ) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Lannett Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Lannett Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Lannett Co (Lannett Co) Business Description

Traded in Other Exchanges
N/A
Address
1150 Northbrook Drive, Suite 155, Trevose, PA, USA, 19053
Lannett Co Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products. It offers solid oral, extended-release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. In addition, the company also provides its products for various medical indications comprising glaucoma, gastrointestinal, migraine, obesity, respiratory, and others. It operates in the segment of generic pharmaceuticals. Its customers include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, and others.
Executives
John C Chapman director 9000 STATE ROAD, PHILADELPHIA PA 19136
Timothy C Crew officer: Chief Executive Officer 9000 STATE ROAD, PHILADELPHIA PA 19136
Patrick G Lepore director 17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Melissa Rewolinski director 9000 STATE ROAD, PHILADELPHIA PA 19136
Jeffrey Farber officer: Secretary
Samuel H Israel officer: Chief Legal Officer 9000 STATE ROAD, PHILADELPHIA PA 19136
John Abt officer: Vice President of Quality 9000 STATE ROAD, PHILADELPHIA PA 19136
John Kozlowski officer: Chief Operating Officer 9000 STATE ROAD, PHILADELPHIA PA 19136
David A Drabik director 9000 STATE RD, PHILADELPHIA PA 19136
Paul Taveira director 9000 STATE ROAD, PHILADELPHIA PA 19136
Albert Iii Paonessa director 9852 NW 2ND COURT, PLANTATION FL 33324
Kevin Smith other: Vice President
Maureen Cavanaugh officer: Senior Vice President and CCOO 9000 STATE ROAD, PHILADELPHIA PA 19136
David Farber officer: Treasurer
Arthur P Bedrosian officer: President P O BOX D 1400, POMONA NY 10970